REFERENCES
- Caravati EM, Grey T, Nangle B, Rolfs RT. Increase in poisoning deaths caused by non-illicit drugs—Utah, 1991–2003. MMWR Morb Mortal Weekly Rep. 2005;54:33–36.
- Rolfs RT, Johnson E, Williams NJ, Sundwall DN. Utah clinical guidelines on prescribing opioids for treatment of pain. J Pain Palliat Care Pharmacother. 2010;24:219–235.
- Johnson EM, Porucznik CA, Anderson JW, Rolfs RT. State-level strategies for reducing prescription drug overdose deaths: Utah's prescription safety program. Pain Med. 2011;12(Suppl 2):S66–S72.
- Lipman AG. Does the DEA truly seek balance in pain medicine? A chronology of confusion that impedes good patient care. J Pain Palliat Care Pharmacother. 2005;19:7–9.
- Craig DS. The Food and Drug Administration risk evaluation and mitigation strategy. J Pain Palliat Care Pharmacother. 2010;24:145–148.
- Coleman JJ. The supply chain of medicinal controlled substances: addressing the Achilles heel of drug diversion. J Pain Palliat Care Pharmacother. 2012;26:233–250
- Kuehn B. Methadone overdose deaths rise with increased prescribing for pain. JAMA. 2012;308:749–750.
- Reisfield GM, Friedman CK. Methadone in the chronic pain patient with a substance use disorder. J Pain Palliat Care Pharmacother. 2012;26:368–370.
- Chou R, Fanciullo GJ, Fine PG, Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10:113–130.